Composition for stabilizing corneal tissue during or after orthokeratology lens wear
View Patent ↗Two types of compositions having an eye-drop delivery system are used during or after an orthokeratology procedure to prevent or retard relaxation of corneal tissue back to the original anterior curvature of the cornea. Each composition functions independently from the others and is a different approach of preparing a stabilizing agent. The first composition is directed to a biologically compatible composition comprising fibril associated collagens with interrupted triple helices (FACITs) and/or small leucine-rich repeat proteoglycans (SLRPs). The fibril associated collagen family includes various types of collagens, such as type VI, type XX, type XII, and type XIV. The small leucine-rich repeat proteoglycans family includes decorin, keratocan, biglycan, epiphycan, lumican, mimecan, and fibromodulin. The second composition includes the enzyme found as a normal component of tissues, plasma, or epidermis, such as transglutaminase.
1. A method for maintaining a desired shape of corneal tissues following an orthokeratological procedure, comprising
administering to a patient a stabilizing agent comprising type VI collagen or decorin, whereby the stabilizing agent stabilizes the corneal tissues to maintain the desired shape.
2. The method of claim 1 wherein the stabilizing agent is applied to the corneal tissues of the patient.
3. The method of claim 1 , wherein the stabilizing agent interacts with collagen fibrils to form bridges connecting the collagen fibrils.
4. The method of claim 3 , wherein the stabilizing agent controls a diameter of the collagen fibrils.
5. The method of claim 3 , wherein the bridges are sufficiently flexible to allow fibril movement within a predetermined range.
6. The method of claim 1 , wherein the stabilizing agent has a concentration within a range from about 40 μg/mL to about 100 μg/mL.
7. A method for maintaining a desired shape of corneal tissue following an orthokeratological procedure, comprising
administering to a patient a stabilizing agent comprising transglutaminase, whereby the stabilizing agent stabilizes the corneal tissue to maintain the desired shape.
8. The method of claim 7 , wherein the stabilizing agent is applied to the corneal tissue of the patient.